ARCHIVES

FDA Committee Okays Carboplatin For Second Line Ovarian Cancer

This article is from The Cancer Letter archive.

Vol. 15 No. 01 | January 6, 1989

Download PDF Visit The Full Archive

Related Articles

Bevacizumab And Irinotecan May Increase Survival Of GBM

October 26, 2007

In Brief: Paul Van Nevel, Director Of NCI Communications, To Retire At Year’s End

November 26, 1999

Fox Chase Joins Plan For Free Cancer Screening

May 9, 1986

NCABP “Anyone With Same Facts Would Have Come To Same Conclusion

October 28, 1994

At Least 25 CCOP Applicants Score High Enough To Virtually Assure Funding; Geography An Issue

May 13, 1983

NCI Cooperative Group Clinical Trials Approved

May 29, 2009